Consolidated Statements of Cash Flows (Parenthetical) |
12 Months Ended |
|---|---|
|
Dec. 31, 2024
CHF (SFr)
| |
| Disclosure | |
| Share of net loss of associates | SFr (2,177,157) |
| Discontinued operations as disclosed below | |
| Disclosure | |
| Net gain on Neurosterix Transaction | 13,943,595 |
| Net gain on Neurosterix Transaction, non-cash items | 8,870,000 |
| Fair value of Neurosterix US Holdings LLC's participation | 9,428,400 |
| Fair value of service agreement | 182,348 |
| Accelerated vesting of equity incentive units of employees and Executive Managers transferred to Neurosterix Pharma Sarl | SFr 1,158,069 |
| Discontinued operations as disclosed below | Neurosterix US Holdings LLC | |
| Disclosure | |
| Percentage of equity interest received | 20.00% |